Hikma Pharmaceuticals Plc · LSE:HIK
Hikma Pharmaceuticals — J.P. Morgan Healthcare Conference 2023
17 slides from Hikma Pharmaceuticals's conference presentation, January 2023
Slide 1: Better health. Within reach. Every day.
Better health. Within reach. Every day. Hikma Pharmaceuticals J.P. Morgan Healthcare Conference January 2023
Slide 2: Disclaimer
Disclaimer This presentation may contain certain statements which are, or may be deemed to be, "forward looking statements" which are prospective in nature with respect to Hikma’s expectations and plans, strategy, management objectives, future developments and performance, costs, revenues and other
Slide 3: Presentation and Q&A participants
JPM Global Healthcare conference 2023 Presentation and Q&A participants Bassam Kanaan Susan Ringdal EVP, Corporate Development and M&A EVP, Strategic Planning and Investor Relations Hikma Pharmaceuticals PLC 3
Slide 4: A well diversified, global generic pharmaceutical business
A well diversified, global generic pharmaceutical business Three global Diversified Businesses revenue stream Strategic financial Manufacturing sites with close flexibility proximity to key markets Little product Lifelong commitment concentration to quality Hikma Pharmaceuticals PLC 4
Slide 5: Consistent long-term performance driving confidence for the future
Consistent long-term performance driving confidence for the future Core revenue Core operating profit Return on invested capital (millions) (millions) (%) +7% +13% 17% CAGR CAGR Average return $632 18.6% $2,553 $566 17.0% 17.1% $2,341 $508 16.2% $2,203 15.1% $2,076 $460 $1,936 $386 22% 23% 24% 25% 2
Slide 6: Diversification of business enabling us to manage market headwinds
Diversification of business enabling us to manage market headwinds Branded Branded 28% 22% 1H22 1H22 revenue Injectables core operating profit Injectables by segment 44% by segment1 61% Generics Generics 27% 17% 1 Core operating profit is $296 million. Before unallocated corporate costs of $47 milli
Slide 7: A world-class, high margin, defensible Injectables business
A world-class, high margin, defensible Injectables business • World-class, high-margin business 1H22 • >$1bn revenue, with a 13% 10 year CAGR revenue Injectables by segment 44% • Core operating margin consistently above 37% since 2014 • Top 3 generic injectable manufacturer in the US by volume1 • Br
Slide 8: Injectables - Building a differentiated pipeline to sustain future growth
Injectables - Building a differentiated pipeline to sustain future growth New markets 1 R&D 2 Partnerships 3 and adjacencies US Injectables pipeline1 Building a portfolio of biosimilars, specialty and complex injectables2 Expansion into Canada through the acquisition of Teligent sterile injectable U
Slide 9: Injectables - Leveraging manufacturing quality and commercial strength to enter US sterile compounding market
Injectables - Leveraging manufacturing quality and commercial strength to enter the attractive US sterile compounding market Launched 503B sterile compounding business in 2022 Market need for Why a Hikma Significant opportunity1 ready-to-administer formats opportunity? We have the competitive $2.3bn
Slide 10: A world-class, high margin, defensible Branded business
A world-class, high margin, defensible Branded business Branded • 3rd largest pharmaceutical company in MENA1 28% 1H22 revenue • 2021 revenue of $669 million by segment • Stable underlying margins • Diversified portfolio of branded generic and in-licensed products focused on chronic illnesses Brande
Slide 11: Delivering growth across our markets supported by our strong commercial capabilities
Delivering growth across our markets supported by our strong commercial capabilities R&D Local Commercial 1 and BD 2 Manufacturing 3 strength Increased prevalence of lifestyle disease is leading to increased demand • Internal R&D focused • 23 plants across the • Over 2,000 sales for chronic medicati
Slide 12: A world-class, high margin, defensible Generics business
A world-class, high margin, defensible Generics business 1H22 • Significant improvement in our business Generics revenue since Columbus acquisition in 2016 by segment 27% • Navigating a period of sustained price erosion • Strong commercial capabilities enabling us to maintain leading position on a n
Slide 13: Generics - Building a diversified portfolio while leveraging manufacturing strength
Generics - Building a diversified portfolio while leveraging manufacturing strength to improve business resilience 1 Pipeline 2 Specialty 3 CMO • Successfully launching new • Building a portfolio of specialty • Leveraging state-of-the-art products products through licensing and manufacturing facilit
Slide 14: Manufacturing strength - Our global capabilities differentiate us from peers
Manufacturing strength - Our global capabilities differentiate us from peers and provide flexibility to capture opportunities We are investing to support a growing global portfolio: • Maintaining best-in-class capabilities in Columbus US • Upgrading our compounding site in the US • Adding new fillin
Slide 15: Pipeline breakdown by segment
Pipeline breakdown by segment Products in Products in Products in 78 US Injectables 119 Branded 23 Generics Cardiovascular Anti- ER Oral Solid Liquid Vial Liquid PFS diabetics 18% 12% CNS 13% 17% 13% 11% 13% Nasal 63% 9% Bag 19% 10% Anti- 5% infectives 48% 9% 6% 3% Lyo Vial Oncology 9% 6% 4% 1% 3% 2
Slide 16: A strong investment case
A strong investment case A solid platform Increasingly diverse Strong balance sheet A clear strategy for growth across portfolio and and a track record for growth all three pipeline of delivering value for businesses shareholders Underlying this is our commitment to act responsibly, by advancing hea
Slide 17: Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC 17
Hikma Pharmaceuticals — J.P. Morgan Healthcare Conference 2023 on 6ix